Shares of clinical-stage biotechnology company Sonnet BioTherapeutics (NASDAQ:SONN) are soaring today after the company announced a 1-for-14 reverse stock split.
Sonnet has undertaken the move to comply with NASDAQ’s minimum price rules and shares are expected to start trading post-split from September 19 onwards.
Read full Disclosure
